One patient means absolutely nothing (placebo or active intervention), however, the publicity is probably good for the company/stock and potentially shareholders.
Time will tell.... it won't be as effective as isotretinoin, but if equally or more effective than other topical products on the market, then the potential market is massive - acne is one of the biggest markets out there.
Then there is the eczema/psoriasis trials - both very large markets...…. Will need to see the overall trial results to see if this is a market maker or not.
Ann: Botanix BTX 1503 Clinical Trial Update, page-19
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.010(2.78%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.0¢ | 33.5¢ | $2.103M | 6.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32406 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 234417 | 5 |
View Market Depth
| Last trade - 16.10pm 02/12/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
